Answer
Koselugo (selumetinib) granules in capsule for opening are indicated as monotherapy for symptomatic, inoperable plexiform neurofibromas in patients with neurofibromatosis type 1 aged 1 year to less than 7 years, and in older patients with swallowing difficulties.
Sources for this answer
- Koselugo 5 mg granules in capsule for openingAstraZeneca UK Limited · emc · SmPC §4.1 Therapeutic Indications · Version 1Document updated
Sources checked